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money saved annually with the Sandimmun Neoral-based main-
tenance immunosuppression regimen was found to be about
776,000 roubles per transplant recipient per year. CONCLU-
SION: Sandimmun Neoral is the leading alternative for
immunosuppression following renal transplantation, i. e. it is
preferable from a clinicoeconomic perspective.
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OBJECTIVES: Standard medicinal care of patients with urge or
mixed urinary incontinence is muscarinic receptor antagonists.
Alternative forms of administration are available for these drugs.
The objective of this analysis was to compare the cost effective-
ness of the only available transdermal oxybutynin patch with
oral long-acting tolterodine tablets in the treatment of patients
with urge or mixed urinary incontinence in Sweden. METHODS:
The efﬁcacy of oxybutynin patches (3.9 mg/day), and tolterodine
tablets (4 mg/day) was compared in a 12 weeks randomized
clinical trial with 361 patients. The study demonstrated a com-
parable clinical efﬁcacy between the treatment alternatives in
number of daily incontinence episodes, average void volume and
QoL. A cost minimization analysis (CMA) was performed based
on this trial where direct medical costs related to drug treatments
and the costs of treating the major adverse events (AE)
(erythema, pruritus, rash, dry mouth, diarrhoea and constipa-
tion) were included. Resource utilization associated with the
treatment of the adverse events in Swedish clinical practice was
assessed by Swedish specialists in the ﬁeld. RESULTS: The CMA
shows that the total costs for 12 weeks tolterodine treatment is
1113.- SEK (~119.- €) per patient while the total costs for 12
weeks oxybutynin treatment is 1067.- SEK (~114.- €). The results
also demonstrate that the cost of treating AEs compose an insig-
niﬁcant fraction of the total treatment costs. This is due to the
low frequency of AEs requiring treatment, together with the low
costs for treating each AE. A number of sensitivity analyses
demonstrate the robustness of the results, including various sce-
narios for extrapolating the ﬁndings over 52 weeks. CONCLU-
SION: This CMA ﬁnds that oxybutynin patches (3.9 mg/day) is
a cost-effective treatment alternative to tolterodine tablets (4 mg/
day) for treating patients with urged or mixed urinary inconti-
nence in Sweden.
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OBJECTIVES: To assess clinical effectiveness and costs of MMF
or TAC use in immunosuppressive treatment from public payer’s
perspective in Poland. METHODS: Results of a SR of published
clinical trials conducted in December 2006 according to Polish
HTA Guidelines were used to assess effectiveness and safety for
immunosuppressive therapy schemes: TAC + AZA + GCS or
MMF + CsA + GCS. Weibull survival function was used to assess
the risk of acute kidney rejection, graftectomy, dialysis, retrans-
plantion (post-transplantation events) caused by used therapy.
Costs of treatment valid from public payer’s perspective were
taken into account. Pharmacotherapy, drug administration and
monitoring, patient monitoring, post-transplantation events
inﬂuenced the total treatment cost. Markov model was used to
assess costs of immunosuppressive therapies. Sensitivity analysis
was conducted according to range of costs of MMF or TAC
(+/-20%) available in Poland, MMF reimbursement categories
and discount rates for effects and costs in line with the Polish
HTA Guidelines (0% or 5%). All calculations were performed
for 2007 (1EUR = 3.8PLN). RESULTS: Indirect comparison
of immunosuppressive therapy schemes were taken into
account: TAC + AZA + GCS and MMF + CsA + GCS (CsA +
AZA + GCS as common comparator). Review of RCTs for these
therapies included in indirect comparison revealed no signiﬁcant
differences in their effectiveness and safety. TAC use was associ-
ated with signiﬁcantly higher costs from public payer’s perspec-
tive compared to MMF (difference: 97457PLN-135616PLN) per
therapy in accordance with assumed reimbursement category for
MMF (lump co-payment–50% co-payment). Sensitivity analysis
conﬁrmed that MMF’s scheme was cheaper compared to TAC’s
scheme from public payer’s perspective in Poland. CONCLU-
SION: MMF’s therapeutic scheme use in place of TAC’s scheme
lead to signiﬁcant savings for public payer in kidney transplant
immunosuppressive therapy in Poland.
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OBJECTIVES: The aim of our study was to assess the health
status and costs of patients with renal failure undergoing hae-
modialysis treatment in Hungary. METHODS: A questionnaire
survey was performed between November-December, year 2006
in the BBraun Dialysis Centre of Kistarcsa. All patients receiving
heamodialysis were invited to participate in the study. Demo-
graphic data, health care utilisation, informal care, transporta-
tion and other disease related expenses were surveyed. A generic
health status measure, the EQ-5D (range -0.6–1) was applied.
Mobility was measured by the Timed Up and Go Test
(normal < 20 sec). Costing was performed using human capital
approach method, productivity loss was based on average gross
wage (629Euro/month). RESULTS: Seventy-one patients (35
women, 36 men) were involved, mean age 62.3(15.0) years,
duration of haemodialysis was mean 3.9(4.2) years. 34 (47.8%)
patients were retired as many as on maintenance of disabled,
1-1-1 was on permanent sick-leave, unemployed or student.
Patients’ residence was mean 18.6(14.2) km from the dialysis
centre, 23(32.4%) had a car in their household, 2(2.8%) drived
on his own and 4(5.6%) were taken by a relative regularly,
57(80.3%) used the centres’ transportation network. 4(5.6%)
came by ambulance as much as travelled by bus or train.
9(12.7%) patients were living alone, 24(33.8%) with spouse,
37(52.1%) with other relatives, 1 in a nursing home, 28(39.4%)
received regular informal care mean 35.8(25.5) hours/week.
EQ-5D score was mean 0.635(0.3) and the score was signiﬁ-
cantly lower (p < 0.01) in all age-groups than in the Hungarian
population. The Up and Go Test was mean 19.89(17.09) sec.
Mean cost was 21 572 Euro/patient/year, direct medical costs
85.4%, direct non-medical costs 5.8%, indirect costs 8.8%.
CONCLUSION: Health status loss is signiﬁcant in chronic renal
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failure, patients’ dependence and risk of falls is high. Direct
medical costs are substantial. Our study offers baseline data for
further health economic analysis in Hungary.
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OBJECTIVES: To estimate annual direct cost due to urinary
incontinence (UI) of women in Iceland in 2004 and to evaluate
proportion of out-of pocket cost for different age groups and
treatments. METHODS: The prevalence calculations are base on
published studies and a questionnaire of 10,000 women report-
ing prevalence, proportion seeking care and out of pocket expen-
ditures. The direct cost estimate included cost for diagnosis,
therapy and routine care. It did not include cost due to the
consequences of the disease or the monetary loss as a result of
seeking treatment. Cost of active treatment and routine care
came from the National Insurance, University Hospital, smaller
hospitals and 7 nursing homes. All cost was from the year 2004
except the cost from the questionnaire and that was adjusted to
the year 2004. Three subgroups of women with UI were identi-
ﬁed. RESULTS: For the largest subgroup 16–64 yrs. old the total
annual direct cost was 4,4 million $ or 132 $ per woman, 35%
was due to active treatment and 70% was out of pocket cost. For
the next largest subgroup 65 yrs. and older the total annual
direct cost was 1,9 million $ or 284 $ per woman, 37% was due
to active treatment and 46% was out of pocket cost. For the
smallest subgroup 65 years and older in nursing homes the total
annual direct cost was 8.3 million $ or 7538 $ per woman.
CONCLUSION: Seventy percent of the annual total direct cost
of UI is due women 65 yrs. and older. This cost will increase
substantially with aging population. Women with UI in nursing
homes generate 55% of the total cost. If the proportion of active
treatment is increased in the younger age group, health care
authorities cost will increase but it could be more cost effective.
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OBJECTIVES: End stage renal disease (ESRD) is associated with
a substantial clinical and economic burden that impacts signiﬁ-
cantly on health-care systems. The objective of this study was to
estimate the direct costs associated with ESRD in the Greek
health care system. METHODS: A cost of illness analysis was
performed using a Markov model to estimate the direct costs
associated with the treatment of ESRD. Clinical inputs were
derived from ERA-EDTA Registry 2004 Annual Report and pub-
lished data of the renal replacement therapy (RRT) in Greece.
The costs for hospital haemodialysis (HD), continuous ambula-
tory peritoneal dialysis (CAPD), automated peritoneal dialysis
(APD) and kidney transplantation (TX) were calculated. All costs
were calculated from the perspective of the Greek health care
system, in 2006 Euros. RESULTS: At the end of 2006, it was
estimated that more than 11,000 patients were receiving RRT.
The total economic burden of the Greek health care system for
the RRT of these patients was estimated at more than 392.746
million Euros during 2006, almost 30% more than 2003, and
represents 0.16% of the gross national product. The average
weighted cost of RRT per patient year was 38,413 Euros.
Although the cost of TX per patient year (after transplant
surgery) was just 20,727 Euros, only 18.6% of the patients with
ESRD received TX. CONCLUSION: The magnitude of the eco-
nomical burden that the public insurance system pays for the
treatment of ESRD in Greece is another reason for developing
strategies to reduce the incidence of ESRD, as well as the cost of
its treatment. Among the latter, an increase of kidney transplan-
tations in national level seems to be a quite effective measure.
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OBJECTIVES: At the end of the year 2006 in Greece, about 74%
of patients with end-stage renal disease (ESRD) were treated with
haemodialysis (HD). Although the percentage of HD is the
highest among the countries of the European Union, the eco-
nomic aspects have not been widely explored. Therefore, the aim
of this study was to estimate the haemodialysis related costs
in Greece from the perspective of the social security system.
METHODS: A cost analysis was performed from the perspective
of the Greek social security system that covers the HD-related
expenses. A decision analysis model was developed with
Microsoft Excel software to simulate clinical decisions and out-
comes. Only direct costs covered by the social security system
were considered in the analysis including drug therapy, clinical
and laboratory monitoring, treating complications, hospitaliza-
tions, HD sessions and transportations. All costs were calculated
in euros, with 2006 as reference year. RESULTS: The total cost
per patient per year was 38,580 euros for the ﬁrst year including
surgical set-up and 37,378 euros thereafter. From the latter cost,
more than 70% accounts for the costs of HD sessions and
hospitalizations. The cost of drug treatment was 8245.07 euros
per patient year, whereas the average annual cost of erythropoi-
etin per patient was 4833.25 euros. The cost of treating vascular
access infections was just 1711.62 euros per patient year. During
2006, the Greek social security system paid 322.529 million
euros for the treatment of ESRD patients with HD. CONCLU-
SION: Haemodialysis is an expensive alternative renal replace-
ment therapy which burdened the Greek social security system
with more than 320 million euros during the year 2006. To
afford dialysis for those in need, smarter, more efﬁcient use of
limited funds is mandatory. Strict control of the use of some
expensive drugs like erythropoietin and decrease of the hospital-
izations may reduce the cost of haemodialysis.
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OBJECTIVES: Payment by Results represents a complete change
to NHS funding, the core of which will be a national tariff price
based on health care resource groupings [HRG]. The renal tariff
is expected to improve ﬁnancial management so it is important
that the tariff level is set to reﬂect actual costs of treatment. The
objective of this study was to obtain detailed costings for auto-
mated PD (APD), continuous ambulatory PD (CAPD), hospital-
based haemodialysis (HD) and satellite-centre-based HD (SHD)
and to identify potential cost differences and cost drivers.
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